Omalizumab: Systemic lupus erythematosus.

An article in Reactions Weekly reports on a case of an elderly man who developed systemic lupus erythematosus (SLE) while being treated with omalizumab for refractory urticaria. The man presented with symptoms such as low-grade fever, fatigue, muscle weakness, and arthralgias, and was found to have arthritis and a maculopapular rash. Further tests revealed positive anti-histone antibodies and elevated levels of ANA and anti-dsDNA, confirming the diagnosis of SLE. The man's treatment was switched to corticosteroids and hydroxychloroquine, and three months after discontinuing omalizumab, his anti-histone antibodies decreased, further supporting the diagnosis of SLE secondary to omalizumab. [Extracted from the article]

Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)